The REVEAL-1 data de-risks Revita's post-GLP-1 weight maintenance thesis ahead of pivotal randomized readouts. Traders should monitor the REMAIN-1 Midpoint Cohort results in Q3 2026 and the REMAIN-1 Pivotal Cohort topline in early Q4 2026 as binary catalysts. The open-label nature and small sample (n=15) warrant caution, but the magnitude of weight maintenance vs. historical GLP-1 withdrawal data is compelling for an early-stage biotech.
Price Chart
Executive Summary
Fractyl Health reported positive one-year open-label data from its REVEAL-1 Cohort, showing that patients who underwent a single Revita procedure maintained ~78% of prior GLP-1-induced weight loss at one year, with 33% continuing to lose weight. This compares favorably to published ~15% weight regain after GLP-1 withdrawal alone. The data supports Revita's potential as a durable, one-time procedural therapy for post-GLP-1 weight maintenance, with upcoming randomized readouts from REMAIN-1 Midpoint (Q3 2026) and Pivotal (early Q4 2026) cohorts as key catalysts.
Key Facts
- Participants retained ~78% of GLP-1-induced total body weight loss one year after a single Revita procedure (n=15).
- Mean total body weight change of 5.3% ± 2.1% at one year; 33% of patients continued to lose weight.
- Published third-party studies show ~15% weight regain after GLP-1 withdrawal alone at similar time points.
- No procedure-related serious adverse events; mild TEAEs in 36% of participants, transient and self-limited.
- Next catalysts: one-year randomized data from REMAIN-1 Midpoint Cohort in Q3 2026; topline six-month randomized data from REMAIN-1 Pivotal Cohort in early Q4 2026.
Financial Impact
No financial data provided; clinical-stage company with no approved products or revenue. Positive data supports valuation re-rating potential for a $121M market cap biotech.
Risk Factors
- Open-label study design with small sample size (n=15 for efficacy) limits statistical reliability.
- Five participants withdrew or were lost to follow-up; two had protocol deviations, introducing potential bias.
- Upcoming randomized data (REMAIN-1) may not replicate open-label results; failure would significantly impair Revita's prospects.
- No revenue or near-term commercialization path; company relies on capital markets for funding.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3306626 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $1.13 | awaiting T+5 | — | $1.08 (−4.42%) |
Oct 16, 2026 10d ago | 8-K | $1.55 $1.08 | ▼ −30.32% | ▼ −30.42% | $1.08 (−30.32%) |
Oct 13, 2026 12d ago | SC 13G | $4.03 $1.33 | ▼ −66.96% | ▼ −65.80% | $1.08 (−73.17%) |
Aug 10, 2026 10w ago | 8-K | $0.7018 $0.7171 | ▲ +2.18% | ▲ +2.58% | $1.08 (+53.89%) |
Aug 10, 2026 10w ago | Press Release | $0.7018 $0.7171 | ▲ +2.18% | ▲ +2.58% | $1.08 (+53.89%) |
Jul 15, 2026 14w ago | 8-K | $0.9100 $0.7580 | ▼ −16.70% | ▼ −15.72% | $1.08 (+18.68%) |
Jun 12, 2026 19w ago | Institutional Cluster | $0.8500 $0.8583 | ▲ +0.98% | ▲ +0.30% | $1.08 (+27.06%) |
Jun 11, 2026 19w ago | Insider Cluster | $0.8500 $0.8583 | ▲ +0.98% | ▲ +0.30% | $1.08 (+27.06%) |
Jun 11, 2026 19w ago | Institutional Cluster | $0.7239 $0.8500 | ▲ +17.42% | ▲ +16.99% | $1.08 (+49.19%) |
Jun 4, 2026 20w ago | 8-K | $0.7340 $0.7240 | ▼ −1.36% | ▲ +1.19% | $1.08 (+47.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers